Abalos to present preclinical data on ABX-001 and its potential to further intensify anti-tumoral effects when combined with bispecific T-cell engagers ... .
-- First-in-class non-oncolytic arenavirus-based approach designed to induce targeted, effective, and durable anti-cancer activity against primary tumors and metastases – ... .
-- Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- ... .